Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CX3CR1 | P49238 | 20/20 | 1.00 |
| ▸ | CXCR2 | P25025 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8797 SCHEMBL29473543 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL30914115 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL212862 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL212398 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL30914151 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL23528828 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL31643602 | 1.00 | CX3CR1 (1.00) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL23828002 | 0.99 | CX3CR1 (0.98) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL23828005 | 0.99 | CX3CR1 (0.98) | CX3CR1CXCR2ADORA1 | |
| Azd-8797 SCHEMBL30288320 | 0.99 | CX3CR1 (0.98) | CX3CR1CXCR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195549-A1 | NEW USE | KANCERA AB (SE) | 2025-06-19 | — | — | US | claimed |
| US-20250195548-A1 | NEW USE | KANCERA AB (SE) | 2025-06-19 | — | — | US | claimed |
| US-20230068240-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2023-03-02 | — | — | US | claimed |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2021-06-24 | — | — | US | claimed |
| US-9440992-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | claimed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | claimed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | claimed |
| EP-1869056-B1 | NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | claimed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | claimed |
| US-20250230170-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | KANCERA AB (SE) | 2025-07-17 | — | — | US | disclosed |
| US-20250195548-A1 | NEW USE | KANCERA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20250195549-A1 | NEW USE | KANCERA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-12264165-B2 | Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom | KANCERA AB (SE) | 2025-04-01 | — | — | US | disclosed |
| US-12060380-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | KANCERA AB (SE) | 2024-08-13 | — | — | US | disclosed |
| US-8088780-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-1869056-B1 | NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | disclosed |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 6/4885ADORA1 60/4885 |
| US-12264165-B2 | Process for the stereoselective preparation of chiral 2-[(hetero) arylalkylsulfanyl]pyrimidines and products obtainable therefrom | CYP2B6, CYP2S1, CYP2D6 | CX3CR1 1795/4885CXCR2 430/4885ADORA1 170/4885 |
| US-20210188873-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, TYMS | CX3CR1 3509/4885CXCR2 1602/4885ADORA1 278/4885 |
| US-12060380-B2 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1 | CX3CR1, CXCR3, CXCR1 | CX3CR1 1/4885CXCR2 16/4885ADORA1 49/4885 |
| US-20230068240-A1 | A Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, TYMS | CX3CR1 3509/4885CXCR2 1602/4885ADORA1 278/4885 |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | CX3CR1, CCR2, CXCR3 | CX3CR1 1/4885CXCR2 11/4885ADORA1 69/4885 |
| US-20250230170-A1 | Process for the Steroselective Preparation of Chiral 2-[(Hetero)Arylalkylsulfanyl]Pyrimidines and Products Obtainable Therefrom | CYP2S1, CYP2B6, CYP2F1 | CX3CR1 3602/4885CXCR2 1814/4885ADORA1 367/4885 |
| US-20250195548-A1 | NEW USE | F12, TNNI3, SERPINC1 | CX3CR1 703/4885CXCR2 441/4885ADORA1 868/4885 |
| US-20250195549-A1 | NEW USE | F12, TNNI3, SERPINC1 | CX3CR1 703/4885CXCR2 441/4885ADORA1 868/4885 |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | CX3CR1, CCR2, CCR5 | CX3CR1 1/4885CXCR2 5/4885ADORA1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.